Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EIF4G1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EIF4G1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EIF4G1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EIF4G1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EIF4G1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EIF4G1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EIF4G1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EIF4G1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000641333 | Oral cavity | NEOLP | translational initiation | 39/2005 | 118/18723 | 5.20e-11 | 6.30e-09 | 39 |
GO:000641734 | Oral cavity | NEOLP | regulation of translation | 97/2005 | 468/18723 | 9.94e-11 | 1.05e-08 | 97 |
GO:003432923 | Oral cavity | NEOLP | cell junction assembly | 88/2005 | 420/18723 | 4.18e-10 | 3.44e-08 | 88 |
GO:003133433 | Oral cavity | NEOLP | positive regulation of protein-containing complex assembly | 58/2005 | 237/18723 | 1.09e-09 | 7.92e-08 | 58 |
GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
GO:005109833 | Oral cavity | NEOLP | regulation of binding | 77/2005 | 363/18723 | 2.91e-09 | 1.76e-07 | 77 |
GO:005109933 | Oral cavity | NEOLP | positive regulation of binding | 46/2005 | 173/18723 | 3.51e-09 | 2.04e-07 | 46 |
GO:004593633 | Oral cavity | NEOLP | negative regulation of phosphate metabolic process | 88/2005 | 441/18723 | 5.20e-09 | 2.87e-07 | 88 |
GO:001056333 | Oral cavity | NEOLP | negative regulation of phosphorus metabolic process | 88/2005 | 442/18723 | 5.82e-09 | 3.15e-07 | 88 |
GO:001820922 | Oral cavity | NEOLP | peptidyl-serine modification | 72/2005 | 338/18723 | 7.84e-09 | 4.09e-07 | 72 |
GO:004232633 | Oral cavity | NEOLP | negative regulation of phosphorylation | 79/2005 | 385/18723 | 8.76e-09 | 4.48e-07 | 79 |
GO:000193332 | Oral cavity | NEOLP | negative regulation of protein phosphorylation | 70/2005 | 342/18723 | 6.77e-08 | 2.61e-06 | 70 |
GO:001604931 | Oral cavity | NEOLP | cell growth | 90/2005 | 482/18723 | 9.23e-08 | 3.43e-06 | 90 |
GO:000218333 | Oral cavity | NEOLP | cytoplasmic translational initiation | 16/2005 | 34/18723 | 9.42e-08 | 3.48e-06 | 16 |
GO:003497632 | Oral cavity | NEOLP | response to endoplasmic reticulum stress | 56/2005 | 256/18723 | 1.39e-07 | 4.84e-06 | 56 |
GO:190188814 | Oral cavity | NEOLP | regulation of cell junction assembly | 47/2005 | 204/18723 | 2.82e-07 | 8.96e-06 | 47 |
GO:000644631 | Oral cavity | NEOLP | regulation of translational initiation | 25/2005 | 79/18723 | 3.75e-07 | 1.15e-05 | 25 |
GO:004572732 | Oral cavity | NEOLP | positive regulation of translation | 35/2005 | 136/18723 | 5.91e-07 | 1.74e-05 | 35 |
GO:003425033 | Oral cavity | NEOLP | positive regulation of cellular amide metabolic process | 39/2005 | 162/18723 | 8.79e-07 | 2.37e-05 | 39 |
GO:003133034 | Oral cavity | NEOLP | negative regulation of cellular catabolic process | 52/2005 | 262/18723 | 8.04e-06 | 1.57e-04 | 52 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF4G1 | SNV | Missense_Mutation | novel | c.4172N>A | p.Cys1391Tyr | p.C1391Y | Q04637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.184C>T | p.Arg62Trp | p.R62W | Q04637 | protein_coding | deleterious(0) | possibly_damaging(0.609) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
EIF4G1 | SNV | Missense_Mutation | | c.2188N>A | p.Glu730Lys | p.E730K | Q04637 | protein_coding | deleterious(0.01) | possibly_damaging(0.905) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.2701N>T | p.Arg901Cys | p.R901C | Q04637 | protein_coding | deleterious(0.01) | benign(0.344) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EIF4G1 | SNV | Missense_Mutation | novel | c.364N>T | p.Val122Phe | p.V122F | Q04637 | protein_coding | deleterious(0.04) | possibly_damaging(0.862) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EIF4G1 | SNV | Missense_Mutation | rs571849011 | c.197C>T | p.Pro66Leu | p.P66L | Q04637 | protein_coding | deleterious(0) | benign(0.098) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | | c.1457N>T | p.Gly486Val | p.G486V | Q04637 | protein_coding | tolerated(0.31) | probably_damaging(0.942) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EIF4G1 | SNV | Missense_Mutation | rs73053766 | c.3791A>G | p.Asn1264Ser | p.N1264S | Q04637 | protein_coding | deleterious(0.05) | benign(0.076) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
EIF4G1 | insertion | Frame_Shift_Ins | novel | c.3123_3124insGTTAA | p.Pro1042ValfsTer59 | p.P1042Vfs*59 | Q04637 | protein_coding | | | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
EIF4G1 | insertion | Nonsense_Mutation | novel | c.3124_3125insAGAGGCAATAATGCATGA | p.Pro1042delinsGlnArgGlnTerCysMetThr | p.P1042delinsQRQ*CMT | Q04637 | protein_coding | | | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |